NCT00452595View on ClinicalTrials.gov

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2004

Study Completion Date

May 31, 2005

Conditions
Major Depressive Disorder
Interventions
DRUG

DVS-233 SR (desvenlafaxine sustained release )

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00452595 - Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter